Novel water-soluble nystatin derivative, being fully water-soluble (up to 1 g/mL) with the same potency of Nystatin but with 13.5 times lower toxicity

Cancer-testis antigen (CTA) with re-expression in numerous cancer types, eliciting spontaneous humoral and cellular immune responses, restricting expression pattern, being a good candidate target for cancer immunotherapy

Anti-microbial agent against Mycobacterium smegmatis and Mycobacterium bovis BCG, binding to DNA and inducing a unique morphological change to mycobacterial bacilli leading the bacterial cell death

Selective nNOS inhibitor and a5-HT1B/1D receptor agonist

Novel potent Hsp90 inhibitor, inducing tumor regression in a genetically engineered mouse model of glioblastoma multiforme

Highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor

Exceptional oxygen transporter, increasing brain tissue oxygen tension (PbtO2) when administered soon after traumatic brain injury (TBI)

Potent, orally active, small-molecule enhancer of SMN2 splicing, binding to and stabilizing the U1 snRNP:5′ss RNA complex

Negative control for NVS-PAK1-1 (8778)

Novel Potent and Selective inhibitor of YEATS proteins

Novel selective bromodomain and extra-terminal domain (BET) protein family inhibitor (BETi ), inducing an ‘activated’ keratinocyte transcriptional profile with reversal of chronic wound biomarkers in human skin ex vivo

Novel potent PKCθ inhibitor

Specific inhibitor of the 25-hydroxyvitamin D(3)-24-hydroxylase (24-hydroxylase)

Novel focal adhesion kinase (FAK) inhibitor, potently blocking kinase activity of FAK along with Aurora A, activated Cdc42-associated kinase 1 (ACK1), Met, insulin receptor (IR), TrkA, and IGF-1R

The first non-peptide somatostatin sst(1) receptor antagonist

Novel nonpeptide bradykinin B1 receptor antagonist

Novel Syk inhibitor

Novel peptide deformylase (PDF) inhibitor; Antibacterial

Potent, orally active dipeptidyl peptidase (DPP)-IV inhibitor

Novel potent and selective p53-HDM2 inhibitor

Novel potent Jak2 type 1 inhibitor

Novel dual inhibitor of TORC1 and TORC2

Novel BCR-ABL Kinase Inhibitor

Novel potent and selective antagonist of somatostatin receptor subtype SST(3)

Novel Inhibitor of the Cysteine Protease Cathepsin K

Novel phosphodiesterase 4D (PDE4D) inhibitor

Novel potent, orally bioavailable CXCR2 receptor antagonist

Novel potent, orally bioavailable CXCR2 receptor antagonist

Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs)

Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs)